Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EMA Plans Guidance To ‘Closely Knit’ Development Of Companion Diagnostics And Drugs

Executive Summary

The European Medicines Agency has taken the first step towards the development of guidance to help optimize the co-development of medicinal products and companion diagnostics.

You may also be interested in...



Policy Prescriptions: User Fees, EMA Worries, PBM Strategies, PRIME Milestones

The US has plenty of new pharma legislation, Europe has plenty of worries about EMA's Brexit move, pharmacy benefit managers give plenty more scrutiny to which products earn a place on formulary. Policy Prescriptions rounds up recent regulatory news and trends reported by sister publication the Pink Sheet.

Officially Here: EU Medical Devices And IVD Regulations Are Published

After some five years of working on the EU's new Medical Devices Regulation and IVD Regulation, the texts that were finally adopted on April 5, have been published in the Official Journal of the European Union.

BioMarin’s Hemophilia Gene Therapy Among Nine Products On Track For EU-Wide Approval

Four orphan drugs and a new COVID-19 vaccine are among the latest products that the European Medicines Agency says should be approved.

Topics

Latest News
UsernamePublicRestriction

Register

PS121219

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel